Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression
PROTEOMICS · 2026-07 · 26 (7) · 28-41
DOI: 10.1002/pmic.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, online erschienen am 27.03.2026. Verfasst von Ha-Song Bae und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Analytical Science and Technology (GRAST), Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proteome. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Chungnam National University Research Grant, Ministry of Science and ICT.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free quantitative proteomic profiling. AS1411 treatment significantly reduced TNBC cell viability and migration. To uncover the underlying mechanisms, we performed global proteomic analysis of AS1411‐treated TNBC cells. Bioinformatic analysis of differentially expressed proteins (DEPs) revealed enrichment of tumor‐associated signaling pathways and protein–protein interaction networks regulated by AS1411. Among the DEPs, ATPase H + ‐transporting accessory protein 1 (ATP6AP1) was markedly downregulated in AS1411‐treated TNBC cells. Functional studies demonstrated that ATP6AP1 knockdown suppressed TNBC cell proliferation and migration, whereas its overexpression enhanced tumorigenic phenotypes. Importantly, modulation of ATP6AP1 expression showed minimal effects on normal breast epithelial cells. Collectively, these findings identify ATP6AP1 as a key downstream mediator of AS1411 and support its potential as a therapeutic target in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Analytical Science and Technology (GRAST), Chungnam National University, Daejeon, Republic of Korea.
- Biometrology group, Division of Biomedical Metrology, Korea Research Institute of Standards and Science, Daejeon, Republic of Korea.
- Department of Animal Science and Technology, National Taiwan University, Taipei City, Taiwan (R.O.C.).
ORCID-Profile: Hyoung-Min Park, I-Hsuan Liu, Jae-Young Kim
Förderung
- National Research Foundation of Korea
- Chungnam National University Research Grant
- Ministry of Science and ICT
- Korea Research Institute of Standards and Science
- Ministry of Science and ICT, South Korea
Zitieren
APA
Bae, H. S., Seo, Y. J., Kim, E. B., Park, H. M., Liu, I. H., Lee, J. E., & Kim, J. Y. (2026). Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression. PROTEOMICS, 26(7), 28-41. https://doi.org/10.1002/pmic.70122
Vancouver
Bae HS, Seo YJ, Kim EB, Park HM, Liu IH, Lee JE, et al. Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression. PROTEOMICS. 2026;26(7):28-41. doi:10.1002/pmic.70122
BibTeX
@article{Bae2026,
author = {Bae, Ha-Song and Seo, Yun-Jeong and Kim, Eun-Bi and Park, Hyoung-Min and Liu, I-Hsuan and Lee, J Eugene and Kim, Jae-Young},
title = {Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression},
journal = {PROTEOMICS},
year = {2026},
volume = {26},
number = {7},
pages = {28--41},
doi = {10.1002/pmic.70122}
}
EUVIMED